Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Infliximab Biosimilar Remsima in Treatment of Chronic Plaque Psoriasis

NCT06043752 is registered in ClinicalTrials.gov with Ghurki Trust and Teaching Hospital as lead sponsor.

NCT NCT06043752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06043752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Infliximab Biosimilar Remsima in Treatment of Chronic Plaque Psoriasis
Lead sponsor
Ghurki Trust and Teaching Hospital
Phase
Phase 4
Overall status
Completed
Start date
March 10, 2022
Completion date
August 5, 2023
Enrollment
51 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis